D
Trevi Therapeutics, Inc. TRVI
$13.35 $0.050.38% NASDAQ
Recommendation
Prev Close
$13.30
Volume
3,626
Avg Vol (90D)
2,036,698
Market Cap
$1.71B
Dividend & Yield
--
52-Week Range
$2.36 - $13.78
P/E (TTM)
--
EPS (TTM)
-$0.37
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Trevi Therapeutics (TRVI) Rises on Takeover Speculation
12/2/2025 - GuruFocus
Trevi Therapeutics edges higher amid takeover speculation
12/2/2025 - Seeking Alpha - Healthcare
Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week High - Still a Buy?
11/27/2025 - MarketBeat
Trevi Therapeutics (TRVI, $13.29) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 26, 2025
11/27/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $13.29) entered Uptrend as Momentum indicator ascends above 0 level on Nov 26, 2025
11/27/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $13.29) RSI Indicator left the overbought zone on November 26, 2025
11/27/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $13.29) price may drop as it broke higher Bollinger Band on Nov 26, 2025
11/27/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $11.36) Stochastic Oscillator left the oversold zone on November 25, 2025
11/26/2025 - Tickeron - Stocks
AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI
11/26/2025 - MarketBeat
The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration
11/24/2025 - Simply Wall St
MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI
11/24/2025 - MarketBeat
Trevi Therapeutics (TRVI): Evaluating Valuation Following Narrowed Loss and Financial Flexibility Moves
11/22/2025 - Simply Wall St
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings
11/22/2025 - MarketBeat
Trevi Therapeutics (TRVI, $10.99) Aroon Indicator entered an Uptrend on November 21, 2025.
11/22/2025 - Tickeron - Stocks
B. Riley Increases Earnings Estimates for Trevi Therapeutics
11/21/2025 - MarketBeat
Trevi Therapeutics (TRVI, $10.65) entered Downtrend as Momentum indicator drops below 0 level on Nov 20, 2025
11/21/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $10.65) Aroon Indicator entered an Uptrend on November 20, 2025.
11/21/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $10.65) Stochastic Oscillator left the oversold zone on November 20, 2025
11/21/2025 - Tickeron - Stocks
Trevi Therapeutics price target raised to $16 from $13 at Leerink
11/20/2025 - TipRanks Financial Blog
Trevi Therapeutics price target raised by $3 at Leerink, here's why
11/20/2025 - The Fly
Trevi Therapeutics (TRVI, $11.04) Aroon Indicator entered an Uptrend on November 19, 2025.
11/20/2025 - Tickeron - Technical Analysis
Trevi Therapeutics (TRVI, $11.31) Aroon Indicator entered an Uptrend on November 18, 2025.
11/19/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $11.35) entered Uptrend as Momentum indicator ascends above 0 level on Nov 17, 2025
11/18/2025 - Tickeron - Stocks
Trevi Therapeutics (TRVI, $11.35) Aroon Indicator entered an Uptrend on November 17, 2025.
11/18/2025 - Tickeron - Stocks
Trevi Therapeutics: Big Cough Data, Bigger Execution Risk
11/17/2025 - SeekingAlpha
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$51.20M
EBIT (TTM)
-$51.35M
Net Income (TTM)
-$45.86M
Balance Sheet
Total Assets (Q)
$199.36M
Total Debt (Q)
$823.00K
Total Liabilities (Q)
$9.57M
Book Value Per Share (Q)
$1.48
Cash Flow
Cash from Operations (TTM)
-$44.01M
Cash from Investing (TTM)
-$87.37M
Cash from Financing (TTM)
$172.20M
Net Change in Cash (TTM)
$40.82M
Filings
Filing Date
Thursday, November 13, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Loading...
Beta
0.48
7-Day Total Return
25.35%
30-Day Total Return
24.88%
60-Day Total Return
75.66%
90-Day Total Return
69.63%
Year to Date Total Return
206.19%
1-Year Total Return
366.78%
2-Year Total Return
1,102.70%
3-Year Total Return
526.76%
5-Year Total Return
345.00%
52-week Low
Dec 11, 2024 - $2.36
52-week High
Nov 28, 2025 - $13.78
Valuation
Market Cap
$1.71B - Small Cap
Enterprise Value
$1.51B
Price/Sales (TTM)
--
Price/Book (Q)
8.99
Dividends and Shares
Shares Outstanding
145.11
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.trevitherapeutics.com
Phone Number
203 304 2499
Address
195 Church Street
New Haven, CT 06510
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients... more
NASDAQ 12/02/2025 4:00PM Eastern Quotes delayed